A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Compare the Efficacy and Safety of Bexagliflozin to Placebo in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control
Phase of Trial: Phase III
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Bexagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Theracos
- 26 Jun 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 09 Mar 2017 Planned End Date changed from 1 Jul 2017 to 1 Apr 2017.